Search our Database of Scientific Publications and Authors

I’m looking for a

    1058 results match your criteria Glucagonoma Syndrome

    1 OF 22

    Peptidomic analysis of endogenous plasma peptides from patients with pancreatic neuroendocrine tumours.
    Rapid Commun Mass Spectrom 2018 Jun 1. Epub 2018 Jun 1.
    Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 0QQ, UK.
    Rationale: Diagnosis of pancreatic neuroendocrine tumours requires the study of patient plasma with multiple immunoassays, using multiple aliquots of plasma. The application of mass spectrometry based techniques could reduce the cost and amount of plasma required for diagnosis.

    Methods: Plasma samples from two patients with pancreatic neuroendocrine tumours were extracted using an established acetonitrile based plasma peptide enrichment strategy. Read More

    Glucagonoma with necrolytic migratory erythema: metabolic profile and detection of biallelic inactivation of DAXX gene.
    J Clin Endocrinol Metab 2018 Apr 23. Epub 2018 Apr 23.
    Division of Diabetes, Endocrinology, and Metabolism, Chiba University Hospital, Chiba, Japan.
    Context: Necrolytic migratory erythema (NME) occurs in approximately 70% of patients with glucagonoma syndrome. Excessive stimulation of metabolic pathways by hyperglucagonemia, which leads to hypoaminoacidemia, contributes to NME pathogenesis. However, the molecular pathogenesis of glucagonoma and relationships between metabolic abnormalities and clinical symptoms remain unclear. Read More

    [Surgical strategies for small sporadic neuroendocrine pancreatic tumors].
    Chirurg 2018 Jun;89(6):422-427
    Sektionsleitung Endokrine Chirurgie, Klinik für Viszeral‑, Thorax- und Gefäßchirurgie, Universitätsklinikum Marburg, Baldingerstraße, 35043, Marburg, Deutschland.
    Small (<2 cm) sporadic neuroendocrine pancreatic neoplasms (pNENs) are a heterogeneous group of neoplasms, which can be separated into functionally active or non-functional tumors. Functionally active pNENs release various hormones, such as insulin, gastrin, glucagon and vasoactive intestinal hormones and therefore lead to severe symptoms independent of their size. The main symptoms include hypoglycemia, coma (insulinoma), diarrhea (gastrinoma, VIPoma), intestinal ulcers (gastrinoma) and hyperglycemia (glucagonoma). Read More

    Management of functional neuroendocrine tumors of the pancreas.
    Gland Surg 2018 Feb;7(1):20-27
    Department of Medical Sciences, Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden.
    Pancreatic neuroendocrine tumors (pNETs) constitute a heterogenous group of malignancies with varying clinical presentation, tumor biology and prognosis. The incidence of pNETs has steadily increased during the last decades with an estimated incidence 2012 of 4.8/100,000. Read More

    A review of cutaneous manifestations within glucagonoma syndrome: necrolytic migratory erythema.
    Int J Dermatol 2018 Jun 16;57(6):642-645. Epub 2018 Feb 16.
    Division of Dermatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
    Necrolytic migratory erythema (NME) is a rare skin disorder that is a cutaneous manifestation of the glucagonoma syndrome. It presents with annular eruptions of migrating erythematous papules and plaques with superficial epidermal necrosis, central flaccid bullae, and crusted erosions located primarily in the intertriginous areas. Treatment with the long-acting somatostatin analog Octreotide is a potential therapy to help ameliorate skin symptoms. Read More

    Imaging features of malignant abdominal neuroendocrine tumors with rare presentation.
    Clin Imaging 2018 Feb 8;51:59-64. Epub 2018 Feb 8.
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address:
    Background: Gastroenteropancreatic neuroendocrine tumors (NETs) are rare entities arising from neuroendocrine cells in the gastroenteric tract and pancreas. The purpose of this article is to present four cases of gastroenteropancreatic NETs that featured a challenging diagnosis.

    Case Presentation: We report a case series of four NETs, each with different features. Read More

    Glucagonoma and the glucagonoma syndrome.
    Oncol Lett 2018 Mar 28;15(3):2749-2755. Epub 2017 Dec 28.
    Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China.
    Glucagonoma is an extremely rare pancreatic α-islet cell tumor and is often accompanied by certain clinical symptoms including necrotizing migratory erythema (NME), diabetes, weight loss and anemia. The objectives of the current review were to discern the clinical features, diagnosis, treatment and prognosis of glucagonoma by evaluating 623 reported cases. A 1998 study reviewed 407 cases and 216 cases were reported in studies published after 1998. Read More

    A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation.
    Clin Nucl Med 2018 Apr;43(4):252-255
    Glucagonoma is an extremely rare, glucagon-secreting neuroendocrine tumor of the pancreas. Only sparse data are available about the characteristics of this tumor in somatostatin receptor imaging and only for the situation of initial diagnosis. We present a series of 3 glucagonoma patients who underwent at least 1 Ga-DOTATATE PET/CT scan. Read More

    Malignant transformation of glucagonoma with SPECT/CT In-111 OctreoScan features: A case report.
    Medicine (Baltimore) 2017 Dec;96(50):e9252
    Department of Radiology, Memorial Sloan Kettering Cancer Center, NY.
    Rationale: Glucagonoma is an uncommon disease but it has been associated with a pattern of symptoms defined as glucagonoma syndrome. These symptoms, if promptly recognized, could help to speed up the diagnosing process.

    Patient Concerns: We report a case of a 68-year-old woman with a pancreatic glucagonoma. Read More

    Glucagonoma syndrome with serous oligocystic adenoma: A rare case report.
    Medicine (Baltimore) 2017 Oct;96(43):e8448
    aDiabetic Foot Center, Department of Endocrinology and Metabolism bDepartment of Pathology cDepartment of Pancreatic Surgery dDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
    Rationale: Glucagonoma and pancreatic serous oligocystic adenoma (SOA) are rare neuroendocrine and exocrine tumors of the pancreas, respectively. The coexistence of glucagonoma syndrome (GS) and SOA is a rare clinical condition and has not yet been reported. Additionally, necrolytic migratory erythema (NME), a hallmark clinical sign of GS, is often misdiagnosed as other skin lesions by clinicians due to their lack of related knowledge, which delays diagnosis of GS and thus exacerbates the prognosis. Read More

    Necrolytic Migratory Erythema: A Forgotten Paraneoplastic Condition.
    J Cutan Med Surg 2017 Nov/Dec;21(6):559-561. Epub 2017 Jun 29.
    1 Department of Dermatology, Saint-Luc Hospital, Montreal University, Montréal, QC, Canada.
    Background: Necrolytic migratory erythema (NME) is most commonly a paraneoplastic condition. It is the dermatologic manifestation classically associated with glucagonoma pancreatic neuroendocrine tumour. Glucagonoma syndrome has been defined by the constellation of secreting tumour associated with overproduction by the α-cells in the pancreatic islets of Langerhans, abnormally elevated blood level of glucagon, and skin findings of NME. Read More

    [Diabetes mellitus secondary to an endocrine pathology : when to think about it ?]
    Rev Med Suisse 2017 May;13(565):1158-1162
    Service d'endocrinologie, diabétologie, hypertension et nutrition, HUG, 1211 Genève 14.
    An endocrine disease can be associated with glucose intolerance or diabetes mellitus, and the latter can falsely be considered as type 2 diabetes. Glycemic imbalance can be a direct or indirect consequence of excessive hormone production. Endocrine diseases such as acromegaly, Cushing's syndrome and pheochromocytoma can increase glucose production and cause insulin resistance. Read More

    Necrolytic Acral Erythema in Seronegative Hepatitis C.
    Case Rep Dermatol 2017 Jan-Apr;9(1):69-73. Epub 2017 Mar 17.
    Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
    Necrolytic acral erythema (NAE) is a distinctive skin disorder. The exact cause and pathogenesis is still unclear. Most studies report an association of NAE with hepatitis C virus (HCV) infection. Read More

    Challenging Differential Diagnosis of Hypergastremia and Hyperglucagonemia with Chronic Renal Failure: Report of a Case with Multiple Endocrine Neoplasia Type 1.
    Intern Med 2017 1;56(11):1375-1381. Epub 2017 Jun 1.
    Department of Diabetes and Endocrinology, Osaka Red Cross Hospital, Japan.
    A 53-year-old woman developed end-stage renal failure during a 15-year clinical course of primary hyperparathyroidism and was referred to our hospital for evaluation of suspected multiple endocrine neoplasia type 1 (MEN1). Genetic testing revealed a novel deletion mutation at codon 467 in exon 10 of the MEN1 gene. Systemic and selective arterial calcium injection (SACI) testing revealed hyperglucagonemia and hypergastrinemia with positive gastrin responses. Read More

    Management of the hormonal syndrome of neuroendocrine tumors.
    Arch Med Sci 2017 Apr 1;13(3):515-524. Epub 2016 Jun 1.
    Department of Endocrinology, Poznan University of Medical Sciences, Poznan, Poland.
    Gastroenteropancreatic neuroendocrine tumors (GEP/NET) are unusual and rare neoplasms that present many clinical challenges. They characteristically synthesize store and secrete a variety of peptides and neuroamines which can lead to the development of distinct clinical syndrome, however many are clinically silent until late presentation with mass effects. Management strategies include surgery cure and cytoreduction with the use of somatostatin analogues. Read More

    B-mode and contrast-enhancement characteristics of small nonincidental neuroendocrine pancreatic tumors.
    Endosc Ultrasound 2017 Jan-Feb;6(1):49-54
    Medical Department, Caritas-Krankenhaus, Uhlandstr. 7 D-97980 Bad Mergentheim, Germany; Sino-German Research Center of Ultrasound in Medicine, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
    Background And Objectives: Imaging of the pancreas for detection of neuroendocrine tumors is indicated as surveillance in multiple endocrine neoplasia type 1 (MEN1) or if typical clinical symptoms combined with hormone production raise the suspicion of a neuroendocrine tumor. Endoscopic ultrasound (EUS) is considered the best imaging modality to detect small pancreatic tumors. However, little is known about how small pancreatic neuroendocrine tumors (pNETs) present on EUS. Read More

    Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas.
    J Pathol 2017 May 27;242(1):90-101. Epub 2017 Mar 27.
    INSERM U1052, Lyon, France.
    Foxa2, known as one of the pioneer factors, plays a crucial role in islet development and endocrine functions. Its expression and biological functions are regulated by various factors, including, in particular, insulin and glucagon. However, its expression and biological role in adult pancreatic α-cells remain elusive. Read More

    Glucagonoma syndrome: report of one case.
    Transl Gastroenterol Hepatol 2016 19;1:70. Epub 2016 Sep 19.
    Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
    A 60-year-old male patient was admitted due to protracted systemic pruritus and erythema for 3 years without an obvious dermatologic cause, which exacerbated in the past 3 months, along with weight loss and diarrhoea. He had significant fasting hyperglycemia and dramatically elevated serum glucagon level in biochemical examination. Elevated chromogranin A (CgA) and neuron-specific enolase (NSE) levels were also manifested, whereas carbohydrate antigen 19-9 (CA-199) and carcinoembryonic antigen (CEA) were unremarkable. Read More

    Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver-α-Cell Axis.
    Diabetes 2017 02;66(2):235-240
    Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
    Glucagon is usually viewed as an important counterregulatory hormone in glucose metabolism, with actions opposing those of insulin. Evidence exists that shows glucagon is important for minute-to-minute regulation of postprandial hepatic glucose production, although conditions of glucagon excess or deficiency do not cause changes compatible with this view. In patients with glucagon-producing tumors (glucagonomas), the most conspicuous signs are skin lesions (necrolytic migratory erythema), while in subjects with inactivating mutations of the glucagon receptor, pancreatic swelling may be the first sign; neither condition is necessarily associated with disturbed glucose metabolism. Read More

    Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation.
    Endocrinol Diabetes Metab Case Rep 2016 21;2016. Epub 2016 Nov 21.
    Metabolic Disease Research , Novo Nordisk A/S, Måløv , Denmark.
    Glucagon stimulates hepatic glucose production by activating specific glucagon receptors in the liver, which in turn increase hepatic glycogenolysis as well as gluconeogenesis and ureagenesis from amino acids. Conversely, glucagon secretion is regulated by concentrations of glucose and amino acids. Disruption of glucagon signaling in rodents results in grossly elevated circulating glucagon levels but no hypoglycemia. Read More

    Imaging of secretory tumors of the gastrointestinal tract.
    Abdom Radiol (NY) 2017 Apr;42(4):1113-1131
    Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler St., Houston, TX, 77030, USA.
    Gastrointestinal secretory tumors, or gastroenteropancreatic neuroendocrine tumors, encompass a wide array of endocrine cell tumors. The significance of these tumors lies in their ability to alter physiology through hormone production as we well as in their malignant potential. Functioning tumors may present earlier due to symptomatology; conversely, non-functioning tumors are often diagnosed late as they reach large sizes, causing symptoms secondary to local mass effect. Read More

    Operation for insulinomas in multiple endocrine neoplasia type 1: When pancreatoduodenectomy is appropriate.
    Surgery 2017 03 15;161(3):727-734. Epub 2016 Nov 15.
    Department of Surgery and Translational Medicine, University of Florence, Florence, Italy.
    Background: Distal pancreatectomy is the most frequent operation for insulinomas complicating multiple endocrine neoplasia type 1 insulinoma, although there are conditions for which a different operative approach might be preferable. In this article, we report the operative experience of a referral center for multiple endocrine neoplasia type 1 insulinoma.

    Methods: Twelve patients underwent operations between 1992 and 2015: 8 underwent a distal pancreatic resection, and 4 underwent a pancreatoduodenectomy. Read More

    Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.
    Oncotarget 2016 11;7(46):74415-74426
    Center for Neuropathology, Ludwig-Maximilians University, Munich, Germany.
    Amplification or overexpression of MYCN is involved in development and maintenance of multiple malignancies. A subset of these tumors originates from neural precursors, including the most aggressive forms of the childhood tumors, neuroblastoma and medulloblastoma. In order to model the spectrum of MYCN-driven neoplasms in mice, we transgenically overexpressed MYCN under the control of the human GFAP-promoter that, among other targets, drives expression in neural progenitor cells. Read More

    The biology of glucagon and the consequences of hyperglucagonemia.
    Biomark Med 2016 Nov 9;10(11):1141-1151. Epub 2016 Sep 9.
    Department of Biomedical Sciences, Faculty of Health & Medical Sciences, University of Copenhagen, Denmark.
    The proglucagon-derived peptide hormone, glucagon, comprises 29 amino acids. Its secretion from the pancreatic α cells is regulated by several factors. Glucagon increases blood glucose levels through gluconeogenesis and glycogenolysis. Read More

    Necrolytic migratory erythema and pancreatic glucagonoma.
    Biomedica 2016 Jun 3;36(2):176-81. Epub 2016 Jun 3.
    Grupo de Microbiología Molecular, Facultad de Medicina, Universidad de La Sabana, Chía, Colombia.
    Necrolytic migratory erythema is a rare paraneoplastic dermatosis that may be the first clinical manifestation of the glucagonoma syndrome, a disorder characterized by mucocutaneous rash, glucose intolerance, hypoaminoacidemia, hyperglucagonaemia and pancreatic glucagonoma. The clinical case of a 45-year-old woman is presented. She had been experiencing weight loss, polydipsia, polyphagia, postprandial emesis, excessive hair loss and abdominal pain for two months. Read More

    Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours.
    Endocr Relat Cancer 2016 09 26;23(9):R423-36. Epub 2016 Jul 26.
    Oxford Center for DiabetesEndocrinology and Metabolism, University of Oxford, Oxford, UK.
    Although recent epidemiological evidence indicates that the prevalence of non-functioning gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) is rising, a significant number of GEP-NETs still present with symptoms related to the secretion of biologically active substances leading to the development of distinct clinical syndromes. In the past, these syndromes were associated with substantial morbidity and mortality due to the lack of specific therapies; however, since the introduction of long-acting somatostatin analogues and medications such as proton pump inhibitors, their control has been greatly improved. As a result, nowadays, the main cause of morbidity and mortality in GEP-NETs is mostly directly related to tumour growth and the extent of metastatic disease. Read More

    Prognostic factors in resected pancreatic neuroendocrine tumours: Experience in 95 patients.
    Cir Esp 2016 Oct 19;94(8):473-80. Epub 2016 Jul 19.
    Servicio de Cirugía, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, España.
    Introduction: The aim of this study was to analyze prognostic factors for survival and recurrence in patients with resected pancreatic neuroendocrine tumors (PNT).

    Methods: Medical records of 95 patients with resected PNT were retrospectively reviewed. The variables studied were: age, sex, form of presentation (sporadic/familial tumors), functionality, type of tumor, localization, type of surgery, tumor size, multifocal tumors and recurrent rate. Read More

    Bone turnover response is linked to both acute and established metabolic changes in ultra-marathon runners.
    Endocrine 2017 Apr 15;56(1):196-204. Epub 2016 Jul 15.
    Laboratory of Experimental Biochemistry & Molecular Biology, IRCCS Istituto Ortopedico Galeazzi, Milano, Italy.
    Bone and energy metabolisms regulation depends on a two-way street aimed at regulating energy utilization. Mountain ultra-marathons are highly demanding aerobic performances that deeply affect the whole body homeostasis. In this study we aimed to investigate and characterize the metabolic profile (in terms of hormones involved in energy metabolism), the inflammatory adipokines, and the bone turnover; in particular the osteocalcin-mediated response has been compared in experienced mountain ultra-marathons runners versus control subjects. Read More

    Glucagonoma syndrome: a review and update on treatment.
    J Eur Acad Dermatol Venereol 2016 Dec 16;30(12):2016-2022. Epub 2016 Jul 16.
    Dermatology and Pathology, Rutgers-New Jersey Medical School, Newark, NJ, USA.
    Glucagonoma syndrome is defined by the presence of an alpha-cell secreting tumour of the pancreas, elevated levels of glucagon, and a characteristic rash called necrolytic migratory erythema (NME). NME is usually a specific and often initial finding of glucagonoma syndrome, but it may occur in other settings unassociated with an alpha-cell pancreatic tumour (pseudoglucagonoma syndrome). Glucagonoma syndrome must be distinguished from pseudoglucagonoma syndrome. Read More

    Pancreatic neuroendocrine tumors: contemporary diagnosis and management.
    Hosp Pract (1995) 2016 Aug 18;44(3):109-19. Epub 2016 Jul 18.
    a Department of Internal Medicine, Division of Gastroenterology and Hepatology , University of Utah School of Medicine, Huntsman Cancer Center , Salt Lake City , Utah , USA.
    Pancreatic neuroendocrine tumors (PNETs) are neoplasms that arise from the hormone producing cells of the islets of Langerhans, also known as pancreatic islet cells. PNETs are considered a subgroup of neuroendocrine tumors, and have unique biology, natural history and clinical management. These tumors are classified as 'functional' or 'non-functional' depending on whether they release peptide hormones that produce specific hormone- related symptoms, usually in established patterns based on tumor subtype. Read More

    Over-expression of Slc30a8/ZnT8 selectively in the mouse α cell impairs glucagon release and responses to hypoglycemia.
    Nutr Metab (Lond) 2016 7;13:46. Epub 2016 Jul 7.
    Section of Cell Biology and Functional Genomics, Division of Diabetes Endocrinology and Metabolism, Department of Medicine, Imperial College London, Imperial Centre for Translational and Experimental Medicine, Hammersmith Hospital, du Cane Road, London, W12 0NN UK.
    Background: The human SLC30A8 gene encodes the secretory granule-localised zinc transporter ZnT8 whose expression is chiefly restricted to the endocrine pancreas. Single nucleotide polymorphisms (SNPs) in the human SLC30A8 gene have been associated, through genome-wide studies, with altered type 2 diabetes risk. In addition to a role in the control of insulin release, recent studies involving targeted gene ablation from the pancreatic α cell (Solomou et al. Read More

    Zinc and skin biology.
    Arch Biochem Biophys 2016 Dec 7;611:113-119. Epub 2016 Jun 7.
    Department of Dermatology, Faculty of Medicine, University of Yamanashi, Yamanashi, 409-3898, Japan.
    Of all tissues, the skin has the third highest abundance of zinc in the body. In the skin, the zinc concentration is higher in the epidermis than in the dermis, owing to a zinc requirement for the active proliferation and differentiation of epidermal keratinocytes. Here we review the dynamics and functions of zinc in the skin as well as skin disorders associated with zinc deficiency, zinc finger domain-containing proteins, and zinc transporters. Read More

    Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors.
    Surg Oncol Clin N Am 2016 Apr 18;25(2):363-74. Epub 2016 Feb 18.
    Department of Surgery, Helen F. Graham Cancer Center, 4701 Ogletown-Stanton Road, S-4000, Newark, DE 19713, USA.
    Pancreatic neuroendocrine tumors are a rare group of neoplasms that arise from multipotent stem cells in the pancreatic ductal epithelium. Although they comprise only 1% to 2% of pancreatic neoplasms, their incidence is increasing. Most pancreatic neuroendocrine tumors are nonfunctioning, but they can secrete various hormones resulting in unique clinical syndromes. Read More

    Glucagonoma and Glucagonoma Syndrome: A Case Report with Review of Recent Advances in Management.
    Case Rep Surg 2016 14;2016:1484089. Epub 2016 Feb 14.
    Department of Radiology, King Hussein Medical Center, Amman 11831, Jordan.
    The rarity of glucagonoma imposes a challenge with most patients being diagnosed after a long period of treatment for their skin rash (months-years). Awareness of physicians and dermatologists of the characteristic necrolytic migratory erythema often leads to early diagnosis. Early diagnosis of glucagonoma even in the presence of resectable liver metastases may allow curative resection. Read More

    A short history of neuroendocrine tumours and their peptide hormones.
    Best Pract Res Clin Endocrinol Metab 2016 Jan 23;30(1):3-17. Epub 2015 Oct 23.
    Yale University School of Medicine, New Haven, CT, USA.
    The discovery of neuroendocrine tumours of the gastrointestinal tract and pancreas started in 1870, when Rudolf Heidenhain discovered the neuroendocrine cells, which can lead to the development of these tumours. Siegfried Oberndorfer was the first to introduce the term carcinoid in 1907. The pancreatic islet cells were first described in 1869 by Paul Langerhans. Read More

    Do glucagonomas always produce glucagon?
    Bosn J Basic Med Sci 2016 Feb 1;16(1):1-7. Epub 2016 Feb 1.
    1: Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark 2: Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
    Pancreatic islet α-cell tumours that overexpress proglucagon are typically associated with the glucagonoma syndrome, a rare disease entity characterised by necrolytic migratory erythema, impaired glucose tolerance, thromboembolic complications and psychiatric disturbances. Paraneoplastic phenomena associated with enteric overexpression of proglucagon-derived peptides are less well recognized and include gastrointestinal dysfunction and hyperinsulinaemic hypoglycaemia. The diverse clinical manifestations associated with glucagon-expressing tumours can be explained, in part, by the repertoire of tumorally secreted peptides liberated through differential post-translational processing of tumour-derived proglucagon. Read More

    Necrolytic migratory erythema associated with fatty liver disease and the psuedoglucagonoma syndrome.
    Dermatol Online J 2016 Sep 15;22(9). Epub 2016 Sep 15.
    Hofstra Northwell School of Medicine, Department of Dermatology, Hempstead.
    We report a 48-year-old woman with a past medical history of psoriasis, nonalcoholic steatohepatitis (NASH), and type II diabetes mellitus, who presented to the emergency department with a 1 week history of erosive annular plaques with associated atrophy and telangiectasias on her legs bilaterally, thighs and buttock, histopathologically consistent with necrolytic migratory erythema. Although classically associated with a pancreatic glucagonoma, this patient experienced this figurate erythema in the setting of fatty liver disease with no glucagonoma. The rarity of pseudoglucagonoma syndrome, or necrolytic migratory erythema occurring in the absence of a glucagonoma, warranted the discussion of this case. Read More

    Different Hormonal Expression Patterns Between Primary Pancreatic Neuroendocrine Tumors and Metastatic Sites.
    Pancreas 2016 08;45(7):947-52
    From the *Department of Surgery and Oncology, †Department of Anatomic Pathology, and ‡Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
    Objectives: Pancreatic neuroendocrine tumors (PNETs) are known to have heterogeneity in terms of their ability to produce multiple hormones. The aim of this study was to evaluate the heterogeneity of PNETs from the viewpoint of hormonal expression.

    Methods: The expressions of 4 representative hormones, gastrin, insulin, glucagon, and somatostatin, in both primary and metastatic lesions, were analyzed by immunohistochemical staining in 20 patients with metastatic PNETs (6 gastrinomas, 1 insulinoma, 1 glucagonoma, and 12 nonfunctioning PNETs [NF-PNETs]). Read More

    1 OF 22